Cyp3a41a Inhibitors
Cyp3a41a inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the Cyp3a41a enzyme, a member of the cytochrome P450 superfamily. Cyp3a41a, like other enzymes in this family, plays a crucial role in the oxidative metabolism of a wide variety of substrates, including endogenous compounds such as hormones, steroids, and fatty acids, as well as exogenous substances like pharmaceuticals and environmental toxins. The enzyme functions by catalyzing the monooxygenation of these substrates, a biochemical process that involves the incorporation of an oxygen atom into the substrate molecule. This oxidative modification typically increases the solubility of the substrates, facilitating their further metabolism or excretion from the body. Cyp3a41a is particularly active in the liver, where it contributes to the detoxification processes and the regulation of metabolic pathways that are essential for maintaining homeostasis.
Inhibitors of Cyp3a41a are generally small molecules that are designed to interact directly with the enzyme's active site, preventing it from catalyzing the oxidation of its natural substrates. These inhibitors may work by occupying the substrate-binding pocket, blocking the natural substrates from accessing the catalytic site, or by inducing conformational changes that reduce the enzyme's catalytic efficiency. The design and development of Cyp3a41a inhibitors require a thorough understanding of the enzyme's three-dimensional structure, particularly the regions involved in substrate recognition and catalytic activity. By inhibiting Cyp3a41a, researchers can explore the enzyme's specific role in various metabolic processes and investigate how its inhibition affects the broader network of cytochrome P450-mediated reactions. The study of Cyp3a41a inhibitors is important for understanding the enzyme's substrate specificity, its interactions with other metabolic enzymes, and its overall contribution to the detoxification and metabolism of a wide range of chemical entities. This research deepens our understanding of the functional diversity within the cytochrome P450 superfamily and underscores the critical role these enzymes play in maintaining the balance of metabolic processes within biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Broad-spectrum antifungal agent known to inhibit Cyp3a41a. By hindering the monooxygenase activity, it disrupts the caffeine oxidase activity, contributing to indirect inhibition of the target protein within the endoplasmic reticulum membrane. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Azole antifungal compound acting as an indirect inhibitor of Cyp3a41a. It disrupts the iron ion binding activity, impacting the monooxygenase activity and contributing to the inhibition of the target protein within the endoplasmic reticulum membrane. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Imidazole antifungal compound acting as an indirect inhibitor of Cyp3a41a. It interferes with the caffeine oxidase activity, impacting the monooxygenase activity and leading to indirect inhibition of the target protein within the endoplasmic reticulum membrane. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
Triazole antifungal agent known to inhibit Cyp3a41a. By interfering with the iron ion binding activity, it impacts the monooxygenase activity, contributing to indirect inhibition of the target protein within the endoplasmic reticulum membrane. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Selective serotonin reuptake inhibitor acting as an indirect inhibitor of Cyp3a41a. It disrupts the monooxygenase activity, impacting both the caffeine oxidase and iron ion binding activities, contributing to indirect inhibition of the target protein within the endoplasmic reticulum membrane. | ||||||
Fluvoxamine | 54739-18-3 | sc-207697 | 25 mg | $321.00 | 1 | |
Selective serotonin reuptake inhibitor with inhibitory effects on Cyp3a41a. By interfering with the iron ion binding activity, it impacts the monooxygenase activity, contributing to indirect inhibition of the target protein within the endoplasmic reticulum membrane. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine H2 receptor antagonist known to inhibit Cyp3a41a. By disrupting the monooxygenase activity, it impacts both the caffeine oxidase and iron ion binding activities, contributing to indirect inhibition of the target protein within the endoplasmic reticulum membrane. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $97.00 $328.00 $676.00 $1467.00 | 6 | |
Antibiotic known to induce Cyp3a41a activity. By enhancing the caffeine oxidase and iron ion binding activities, it stimulates the monooxygenase activity and contributes to indirect activation of the target protein within the endoplasmic reticulum membrane. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Synthetic glucocorticoid with inhibitory effects on Cyp3a41a. By suppressing the iron ion binding activity, it impacts the monooxygenase activity, contributing to indirect inhibition of the target protein within the endoplasmic reticulum membrane. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker known to inhibit Cyp3a41a. By interfering with the caffeine oxidase activity, it impacts the iron ion binding activity and contributes to indirect inhibition of the target protein within the endoplasmic reticulum membrane. | ||||||